JohnHarrisonKrystalMD

Addiction

Robert L. McNeil, Jr. Professor of Psychiatry and Professor of Neuroscience; Chair, Department of Psychiatry; Chief of Psychiatry, Yale-New Haven Hospital; Director: NIAAA Center for the Translational Neuroscience of Alcoholism ; Director, Clinical Neuroscience Division, VA National Center for PTSD (VA Connecticut); Co-Director, Yale Center for Clinical Investigation, Yale University

Join to view full profile

Dr. Krystal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Krystal's full profile

Already have an account?

Office
300 George St. #901
New Haven, CT 06511
Phone+1 203-785-6396

Fax+1 203-785-6196

Summary

Dr. John Krystal is the McNeil Professor of Translational Research, Professor of Psychiatry, Neuroscience, and Psychology, Chair of Psychiatry, and Co-Director of the Yale Center for Clinical Investigation at Yale. He is an expert on the neurobiology and treatment of psychiatric disorders including schizophrenia, alcohol use disorder, PTSD, and depression. His laboratory conducted discovered the rapid antidepressant effects of ketamine in depressed patients, leading to the FDA approval of Esketamine, the first mechanistically novel antidepressant in 50 years. For this work, he, Dennis Charney, and Husseini Manji shared the Sarnat Prize of the National Academy of Medicine. He also serves as Director of the Clinical Neuroscience Division of the National Center for PTSD (VA) and the NIAAA Center for the Translational Neuroscience of Alcohol. He is a member of the National Academy of Medicine; Fellow of the American Association for the Advancement of Science; editor of Biological Psychiatry; Vice President of the Scientific Council of the Brain and Behavior Research Foundation, and co-founder of Freedom Biosciences.

Education & Training

Yale-New Haven Medical CenterResidency, Psychiatry, 1985 - 1988
Yale-New Haven Medical CenterInternship, Transitional Year, 1984 - 1985
Yale School of MedicineClass of 1984

Certifications & Licensure

CT State Medical License 1986 - 2026
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

Rhoda and Bernard Sarnat International Prize in Mental Health National Academy of Medicine, 2023
Elected Member Institute of Medicine, 2010

Clinical Trials

GABA-glutamate Interactions and Psychosis Start of enrollment: 2007 Jan 01
Completed
Phase 1
Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects Start of enrollment: 1997 Oct 01
Completed
Not Applicable
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects Start of enrollment: 2008 Aug 01
Completed
Not Applicable
Biomarker Assessment of Glutamatergic Target Engagement Start of enrollment: 2014 May 01
Completed
Phase 4
A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD) Start of enrollment: 2016 Nov 17
Terminated
Not Applicable
CAP-Ketamine for Antidepressant Resistant PTSD Start of enrollment: 2016 Apr 18
Completed
Phase 2
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Start of enrollment: 2018 Nov 29
Completed
Phase 1
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia Start of enrollment: 2021 Mar 02
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Return on Investment of Enhanced Behavioral Health Services.
Matt Hawrilenko, Casey Smolka, Emily Ward, Geetu Ambwani, Millard Brown
JAMA Network Open. 2025-02-03
Gamma oscillations and excitation/inhibition imbalance: parallel effects of N-methyl D-aspartate receptor antagonism and psychosis.
Brian J Roach, Judith M Ford, Spero Nicholas, Jamie M Ferri, Handan Gunduz-Bruce
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 2025-01-18
1 citations
Psilocybin: From Psychiatric Pariah to Perceived Panacea.
Gregory A Fonzo, Aaron S Wolfgang, Bryan R Barksdale, John H Krystal, Linda L Carpenter
The American Journal of Psychiatry. 2025-01-01

Journal Articles

Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia
Mohini Ranganathan, John H Krystal, JAMA Network Open
A Multicenter Study of Ketamine Effects on Functional Connectivity: Large Scale Network Relationships, Hubs and Symptom Mechanisms
Ragy R Girgis, Richard J Maddock, John D Ragland, Daniel C Javitt, Cameron S Carter, Joshua T Kantrowitz, Jeffrey Lieberman, John H Krystal, Lawrence S Kegeles, Willia..., ScienceDirect
Celebrating 50 Years of Biological Psychiatry: To the Future, and Beyond
John Krystal, MD, Biological Psychiatry
The Effects of Ketamine on Prefrontal Glutamate Neurotransmission in Healthy and Depressed Subjects
Lynnette A Averill, Chadi G Abdallah, John H Krystal, Irina Esterlis, Gerard Sanacora, Nature
Archival Report Thalamic Cortical Error–Related Responses in Adult Social Drinkers: Sex Differences and Problem Alcohol Use
John Krystal, MD, ScienceDirect
Join now to see all

Authored Content

Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.govMay 2020
Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.govMay 2020
Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.govMay 2020
Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.govMay 2020
Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.govMay 2020
F131. Genome-Wide Association Study Identifies Glutamate Ionotropic Receptor GRIA4 as a Risk Gene for Comorbid Nicotine Dependence and Major DepressionApril 2018
Join now to see all

Press Mentions

FDA Approves 'Ketamine' Nasal Spray for Depression — Here's Everything You Need to KnowJanuary 31st, 2025
Finally, a New Drug for Posttraumatic Stress Disorder?December 20th, 2024
Combination Therapy Improves PTSD SymptomsDecember 18th, 2024
Join now to see all

Grant Support

Pilot CoreNational Institute On Alcohol Abuse And Alcoholism2011
Administrative CoreNational Institute On Alcohol Abuse And Alcoholism2006–2011
Center For The Translational Neuroscience Of AlcoholismNational Institute On Alcohol Abuse And Alcoholism2001–2011
Cortical GABA Function In AlcoholismNational Institute On Alcohol Abuse And Alcoholism1999–2011
The Interactive Impact Of Cocaine And Schizophrenia On Prefrontal FunctionNational Institute On Drug Abuse2008–2010
A PET Study Of Ventral Striatum Dopamine Release DeficitsNational Institute On Alcohol Abuse And Alcoholism2007–2010
Ctr For Translational Neuroscience Of AlcoholNational Institute On Alcohol Abuse And Alcoholism2006–2010
Amino Acid Neurotransmitter Dysregulation In AlcoholismNational Institute On Alcohol Abuse And Alcoholism2004–2008
Symposium On Neuroimaging In AlcoholismNational Institute On Alcohol Abuse And Alcoholism2007
Moderate Human NMDA Receptor Function And Ethanol ResponseNational Institute On Alcohol Abuse And Alcoholism2007
Pilot Data Collection In Collaboration With The Ctna CoresNational Institute On Alcohol Abuse And Alcoholism2006–2007
Novel Glutamatergic Detoxification StrategiesNational Institute On Alcohol Abuse And Alcoholism2004–2006
Admistrative CoreNational Institute Of Mental Health2004
Symposium On Neuroimaging In AlcoholismNational Institute On Alcohol Abuse And Alcoholism2003
Amino Acid Neurotransmitter Dysregulation In AlcoholismNational Institute On Alcohol Abuse And Alcoholism1999–2003
Core--Statistics And Data ManagementNational Institute On Alcohol Abuse And Alcoholism2001–2002
Naltrexone Blockade Of NMDANational Institute On Alcohol Abuse And Alcoholism2000–2002
Core--Laboratory For Developmental NeurochemistryNational Institute Of Mental Health1998–2000
Core--Clinical Neuroscience And Experimental TherapeuticsNational Institute Of Mental Health1998–2000
Cortical GABA Levels In Schizophrenics/Detoxified Alcoholics/NormalsNational Center For Research Resources1996–1999
NMDA Dysregulation In AlcoholismNational Institute On Alcohol Abuse And Alcoholism1995–1997